1. Scrip
  2. >>R&D

Hanmi Halts Olmutinib Development After Alliances Crumble

 
• By Jung Won Shin

Hanmi is set to focus on other assets in its innovative drug pipeline after it ends development of novel lung cancer drug olmutinib amid ZAI Lab’s recent cancellation of a licensing agreement with the South Korean pharma.

Hanmi Pharmaceutical
HANMI CULLS OLMUTINIB

Hanmi Pharmaceutical Co. Ltd. has decided to stop all further development of its third generation EGFR inhibitor Olita  (olmutinib) following ZAI Lab Ltd.’s return of rights in the China region to the drug.

The South Korean company will instead focus on the development of its 20 other innovative drug assets including the novel...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.